Enhancement of recovery from mental illness with l-methylfolate supplementation.

about

Enhancement of recovery from mental illness with l-methylfolate supplementation.

Item

http://www.wikidata.org/entity/Q39361549

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Enhancement of recovery from mental illness with l-methylfolate supplementation.

@en

Enhancement of recovery from mental illness with l-methylfolate supplementation.

@nl

type

Item

label

Enhancement of recovery from mental illness with l-methylfolate supplementation.

@en

Enhancement of recovery from mental illness with l-methylfolate supplementation.

@nl

prefLabel

Enhancement of recovery from mental illness with l-methylfolate supplementation.

@en

Enhancement of recovery from mental illness with l-methylfolate supplementation.

@nl

P1476

Enhancement of recovery from mental illness with l-methylfolate supplementation

@en

P2093

Gerald Martone

http://www.w3.org/2001/XMLSchema#string

P2860

Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials.

L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials.

Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.

Folate, homocysteine, and negative symptoms in schizophrenia.

Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review.

Randomized multicenter investigation of folate plus vitamin B12 supplementation in schizophrenia

Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial.

Combining antidepressant therapies from the initiation of treatment: a paradigm shift for major depression.

Long-term efficacy, safety, and tolerability of L-methylfolate calcium 15 mg as adjunctive therapy with selective serotonin reuptake inhibitors: a 12-month, open-label study following a placebo-controlled acute study.

Correlation of clinical response with homocysteine reduction during therapy with reduced B vitamins in patients with MDD who are positive for MTHFR C677T or A1298C polymorphism: a randomized, double-blind, placebo-controlled study.

P304

331-334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/PPC.12227

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Gerald Martone

P577

2017-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28597528

http://www.w3.org/2001/XMLSchema#string